Antithrombotic Properties of Dermatan Sulphate (MF 701) in Haemodialysis for Chronic Renal Failure

Summary

The therapeutic potential of the glycosaminoglycan (GAG), dermatan sulphate (DS), as an antithrombotic agent in humans has yet to be established. We have performed dose ranging studies of DS to determine its effectiveness as an antithrombotic agent in patients (n = 6–8) undergoing haemodialysis for chronic renal failure. In an initial study, Study 1, i.v. bolus doses of 2–4 mg/kg and 5–6 mg/kg DS were given to patients dialysing with polyacrylonitrile hollow fibre (PAN HF) membranes. In a second crossover study, Study 2, performed using cuprophane hollow fibre (CHF) membranes, i. v. bolus doses of 3 mg/kg and 6 mg/kg DS were compared to a standard unfractionated heparin (UFH) regime that has been shown previously to inhibit fibrin formation. Further infusion studies, Study 3 and Study 4 evaluated the antithrombotic efficacy of an i. v. DS bolus of 3 mg/kg plus an i. v. infusion of DS 0.6 mg kg^-1 h^-1 and a DS bolus of 5 mg/ kg plus an infusion of 1 mg kg^-1 h^-1 over 5 h, respectively. These studies were compared to standard UFH regimes in a randomised crossover design. Plasma levels of fibrinopeptide A (FPA) and thrombin-antithrombin (TAT) were used as markers of fibrin formation and thrombin generation during dialysis using both membranes.

The changes in DS concentration following administration of the different doses were similar in Studies 1 and 2. However, the effectiveness of DS as an anticoagulant appeared to depend markedly on the different dialyser types used in the two studies. In Study 1, 13/14 dialyses required additional UFH to complete a normal ~6 h session and DS was unable to prevent thrombin and fibrin formation, as determined by measurement of plasma FPA and TAT. However, some dose related effects were observed in the levels of these markers. Furthermore, DS levels correlated with those of FPA and TAT. In Study 2, increasing doses of DS (3 mg/kg and 6 mg/kg), allowed longer dialysis sessions (mean 4.57 h c.f. 5.25 h), approaching that obtained with UFH regime (5.86 h). FPA and TAT generation were incompletely suppressed by both doses of DS; FPA rose significantly compared to that observed with the UFH regime, while TAT did not. While no significant differences in the activation markers were observed between the two DS doses, DS levels, taken as a whole, showed significant negative correlations with those of FPA and TAT Little effect on the KCCT was seen.

In Study 3, 3/6 patients required additional UFH (mean dialysis duration with DS 4.33 h c. f. 5.67 h with UFH). Mean DS levels were maintained between 35–40 µg/ml. Mean plasma FPA levels were maintained at constant levels throughout dialysis following DS administration but were higher than those observed following the UFH regime. In Study 4 mean DS levels were

• REFERENCES

• 1 Tollefsen DM, Petska CA, Monafo WJ. Activation of Heparin Cofactor II by Dermatan Sulphate. J Biol Chem 1983; 258: 6713-6716
• 2 Tollefsen DM, Peacock ME, Monafow J. Molecular size of dermatan sulphate oligosaccharides required to bind and activate heparin cofactor II. J Biol Chem 1986; 261: 8854-8858
• 3 Griffith MJ, Marbet GA. Dermatan sulphate and heparin can be fractionated by affinity for heparin cofactor II. Biochem Biophys Res Commun 1983; 112: 663-670
• 4 Buchanan MR, Boneu B, Ofosu F, Hirsh J. The relative importance of thrombin inhibition and factor Xa inhibition to the antithrombotic effects of heparin. Blood 1985; 65: 198-201
• 5 Fernandez F, Van Ryn J, Ofosu FA, Hirsh J, Buchanan MR. The haemorrhagic and antithrombotic effects of dermatan sulphate. Br J Haematol 1986; 64: 309-317
• 6 Merton RE, Thomas DP. Experimental studies on the relative efficacy of dermatan sulphate and heparin as antithrombotic agents. Thromb Haemostas 1987; 58: 839-842
• 7 Ireland H, Lane DA, Curtis JR. Objective assessment of heparin requirements for haemodialysis in humans. J Lab Clin Med 1984; 103: 643-652
• 8 Lane DA, Flynn A, Ireland H, Anastassiades E, Curtis JR. On the evalutation of heparin and low molecular heparin in haemodialysis for chronic renal failure. Haemostasis 1986; 16: 38-47
• 9 Dupouy D, Sié P, Dol F, Boneu B. A simple method to measure dermatan sulphate at sub-microgram concentrations in plasma. Thromb Haemostas 1988; 60: 236-239
• 10 Ireland H, Lane DA, Wolff S, Foadi M. In vivo platelet release in myeloproliferative disorders. Thromb Haemostas 1982; 48: 41-45
• 11 Lane DA, Ireland H, Wolff S, Grant R, Jennings S, Allen-Mersh T. Plasma concentrations of fibrinopeptide A, fibrinogen fragment Bbl-42 and b-thromboglobulin following total hip replacement. Thromb Res 1982; 26: 111-118
• 12 Boisclair M. Improved methods for the detection of an increased tendency towards thrombosis. PhD Thesis. University of London, London: 1992
• 13 Agnelli G, Cosmi B, Di Filippo P, Ranucci V, Veschi F, Longetti M, Renga C, Barzi F, Gianese F, Lupattelli L, Rinonapoli E, Nenci GG. A randomised double blind placebo controlled trial of dermatan sulfate for prevention of deep vein thrombosis in hip fracture. Thromb Haemostas 1992; 67: 203-208
• 14 Nurmohamed MT, Hoek JA, Ten Cate JW, Krediet RT, Buller HR. Coagulation studies with dermatan sulphate in six chronic haemodialysis patients. Thromb Haemostas 1989; 62: 489
• 15 Nurmohamed MT, Heck JA, Ten Cate JW, Krediet RT, Buller HR. A randomised cross-over study comparing the efficacy and safety of two dosages of dermatan sulphate and standard heparin in six chronic haemodialysis patients. Br J Haematol 1990; 76 (Suppl1): 23-56
• 16 Nurmohamed MT, Roggekamp M, Buller HR, Erkamp R, Stevens P, Ten Cate JW. A randomised cross-over study of dermatan sulphate and combination with heparin as anticoagulant in chronic haemodialysis patients. Thromb Haemostas 1991; 65: 925 (abstr 816)
• 17 Ireland H, Rylance PB, Kestevan P. Heparin as an anticoagulant during extracorporeal circulation. In: Heparin: Chemical and Biological Properties, Clinical Applications. Lane DA, Lindahl U. (eds) Edward Arnold, London: 1989. pp 549-574
• 18 Ireland HA, Boisclair M, Lane DA, Thompson E, Curtis JR. Hemodialysis and heparin. Alternative methods of measuring heparin and of detecting activation of coagulation. Clin Nephrol 1991; 35: 26-34
• 19 Dol F, Houin G, Rostin M, Montastruc JL, Dupouy D, Gianese F, Sie P, Boneu B. Pharmacokinetics and pharmacodynamics of dermatan sulfate in man. Blood 1989; 74: 1577-1582
• 20 Dawes J, McLaren M, Forbes C, Belch JJ, Lane DA, Bray B, McEwen J, Houin G, Gianese F. The pharmacokinetics of dermatan sulphate MF701 in healthy human volunteers. Br J Clin Pharmacol 1991; 32: 361-366